These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24197066)

  • 1. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of the phosphate binder, lanthanum carbonate.
    Damment SJ
    Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of efficient phosphate binding on bone in chronic renal failure rats.
    Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
    Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
    Pierce D; Hossack S; Poole L; Robinson A; Van Heusen H; Martin P; Smyth M
    Nephrol Dial Transplant; 2011 May; 26(5):1615-21. PubMed ID: 20921291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
    Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
    Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
    Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
    Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.
    Nikolov IG; Joki N; Nguyen-Khoa T; Guerrera IC; Maizel J; Benchitrit J; Machado dos Reis L; Edelman A; Lacour B; Jorgetti V; Drüeke TB; Massy ZA
    Nephrol Dial Transplant; 2012 Feb; 27(2):505-13. PubMed ID: 21705467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
    Ginsberg C; Zelnick LR; Block GA; Chertow GM; Chonchol M; Hoofnagle A; Kestenbaum B; de Boer IH
    Nephrol Dial Transplant; 2020 Apr; 35(4):616-623. PubMed ID: 32160298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
    Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
    Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
    Zhou T; Li H; Xie W; Lin Z
    Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.